For General Information, page-2785

This is great summary George. Thanks. The partnering/licensing model carries significantly less risk and arguably nearly equivalent value over the longer term (assuming all markets are licensed and a buyer would acquire ATTL1102 on FDA approval) vs 'going it alone' and ANP becoming a drug manufacturer/distributor, which carries an incredible amount of execution risk and therefore a very different risk rating. Following James presentation at the open house meeting, like you, I am left feeling the tide has well and truly turned and that value will be created much sooner, than later....